IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Clarification Announcement
- Termination of Supply Agreement
- Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
- Imugene HER-Vaxx Clinical Trial Collaboration with Merck
Later from Imugene
- Imugene doses first patient in VAXINIA Phase 1 trial
- Final HER-Vaxx Phase 2 Trial Overall Survival Results
- Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
- First cohort 3 patient dosed in clinical trial of CHECKvacc
- Annual Report and Appendix 4E
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene